Modern aspects of the natural course of chronic viral hepatitis B

Abstract

Currently there are about 400 million people infected with the hepatitis B virus, including five million people - in Russia. A serious problem is the development of complications of chronic viral hepatitis’ - liver cirrhosis and hepatocellular carcinoma, from which eventually 20-35% of patients die. Undoubtedly, the outstanding science achievement of the XX century was the creation of a genetically engineered vaccine against hepatitis B. The pursued immunizations on a global scale has led to significant results - reduction of the number of cases of acute forms of viral hepatitis B, the frequency of formation of the chronic variant of the disease. Despite these successes, there remains the problem of prevention of the perinatal transmission path. Identified were the risk factors for neonatal infection, amongst which the most significant are the presence of the antigen of the hepatitis B virus, which is not a part of the Dane particles (HBEAg), and the level of viremia prior to delivery. The basis of prevention is an active-passive immunization, which helps prevent infection in infants in 90-95% of cases. Encouraging results (reduction in the risk of infant infection) were obtained in studies of antiviral therapy in the III trimester of pregnancy. The introduction of new molecular biological diagnostic methods (polymerase chain reaction) made it possible to determine the genetic material of the virus in serum and tissues, the presence of mutations and genetic variability of the virus. At present, identified are the factors that determine the progression of the disease, the efficacy of antiviral therapy. Identified are the new variants of the clinical course of viral hepatitis B, depending on the profile of the serological (antigen-antibody) markers. The latent course of viral hepatitis B deserves special attention. The serological feature of this variant is the presence of «isolated» antibodies and/or deoxyribonucleic acid of the virus, or the absence of all markers of hepatitis B. It is obvious that patients with a latent course of infection pose a real threat in spreading viral hepatitis B.

Keywords

viral hepatitis B / serological markers of hepatitis B / latent course / prevention of perinatal infection / active-passive immunization / antiviral therapy

References

[1] Абдрахманов Д.Т. Хронический гепатит В и D. - М.: ГЭОТАР-Медиа, 2010. - 286 с.

[2] Бацких С.Н. Латентная HBV-инфекция: безобидный лабораторный феномен или серьёзная клиническая проблема? // Гепатологический форум (приложение к журналу «Фармакология и терапия»). - 2010. - №3. - С. 2-8.

[3] Игнатова Е.М. Хронический гепатит С и беременность // Клинич. гепатол. - 2009. - №5. - С. 32-38.

[4] Кюрегян К.К., Попова О.Е. Скрытая ВГВ-инфекция в Российской Федерации - результаты популяционного исследования // Мир вирусн. гепат. - 2009. - №3. - С. 3.

[5] Мукомолов С.Л., Левакова И.А., Васильева В.А. и др. Современные эпидемиологические особенности вирусного гепатита В // Мир вирусн. гепат. - 2009. - №3. - С. 19-20.

[6] Оганов Р.Г., Хальфин Р.А. Рекомендации по профилактике вирусного гепатита // Клин. гепатол. - 2006. - №3. - С. 40-46.

[7] Татотченко В.К. Национальный календарь профилактических прививок // Вакцинация (информационный бюллетень). - 2008. - №3. - С. 4-5.

[8] Фазылов В.Х., Якупова Ф.М. Семейные очаги хронического вирусного гепатита В: эпидемиологические характеристики и результаты иммунопрофилактики // Обществен. здоров. и здравоохр. - 2008. - №3. - С. 31-34.

[9] Шахгильдян И.В., Михайлов М.И., Онищенко Г.Г. Парентеральные вирусные гепатиты (эпидемиология, диагностика, профилактика). - М.: ГОУ ВУНМЦ МЗ РФ, 2003. - 384 с.

[10] Шифф Ю.Р, Соррел М.Ф., Мэддрей У.С. Вирусные гепатиты и холестатические заболевания / Пер. с англ. В.Ю. Хохлатова. Под ред. В.Т. Ивашкина, Е.А. Климовой, И.Г. Никитина, Е.Н. Широковой. - М.: ГЭОТАР-Медиа, 2010. - 408 с.

[11] Aranz-Ruiz P., Norden H., Robertson B.H. et al. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in central America // J. Gen. Virol. - 2002. - Vol. 83. - P. 2059-2073.

[12] Benvegnu L., Gios M., Boccato S. et al. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications // Gut. - 2004. - Vol. 53. - P. 744-749.

[13] Beshimova D., Enaleeva D.S., Gaifullina E.G. The role of HBcor-Ab in the donor blood testing // Liver under Constant Attack From Fat to Viruses. Falk Symposium №167 (Sept. 20-21, 2008). - Mainz, Germany, 2008. - P. 10.

[14] Borg M.J., Leemans W.F., Man R.A., Janssen H.L. Exacerbation of chronic hepatitis B infection after delivery // J. Viral. Hepatol. - 2008. - Vol. 15. - P. 37-41.

[15] Brunetto M.R. Predicting response to hepatitis B virus therapy // Hepatology. - 2009. - Vol. 49. - P. 1141.

[16] Burk R.D., Hwang L.Y., Ho G.Y. et al. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load // J. Infect. Dis. - 1994. - Vol. 170. - P. 1418-1423.

[17] Bzowej N.H. Hepatitis B therapy in pregnancy // Curr. Hepat. Rep. - 2010. - Vol. 9. - P. 197-204.

[18] Chan H.L., Tsang S.W., Leung N.W. et al. Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection // Am. J. Gastroenterol. - 2002. - Vol. 97. - P. 1211-1215.

[19] Chu C.J., Liaw Y.F. Natural history of chronic hepatitis B virus infection: an immunopathological study // J. Gastroenterol. Hepatol. - 1997. - Vol. 12. - P. 218-222.

[20] Chu C.J., Hussain M., Loc A.S. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection // Hepatology. - 2002. - Vol. 36. - P. 1408-1415.

[21] Cohen Stuart J.W., Velema M., Schuurman R. et al. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy // J. Med. Viral. - 2009. - Vol. 81. - P. 441-445.

[22] EASL Clinical Practice Guidelines: Management of chronic hepatitis B // J. Hepatology. - 2009. - Vol. 50. - P. 227-242.

[23] Fattovich G., Bortolotti F., Dorato F. et al. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors // J. Hepatology. - 2008. - Vol. 48. - P. 335-352.

[24] Georgiadou S.P., Zachou K., Rigopoulou E. et al. Occult hepatitis B virus infection in Greekpatients with chronic hepatitis C and patients with diverse nonviral hepatitis diseases // J. Viral. Hepat. - 2004. - Vol. 11. - P. 356-365.

[25] Hadziyanis S., Vassilopous D. Hepatitis B e antigen-negative chronic hepatitis B // Hepatology. - 2001. - Vol. 34. - P. 617-624.

[26] Hall A., Kane M., Rouze C. et al. Multiple sclerosis and hepatitis B vaccine? // Vaccine. - 1999. - Vol. 17. - P. 2473-2475.

[27] Kao J.H., Chen P.J., Lai M.Y. et al. Hepatitis B genotypes correlate with clinical outcome in patients with chronic hepatitis B // Gastroenterology. - 2000. - Vol. 118. - P. 554-559.

[28] Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention // J. Clin. Virol. - 2005. - Vol. 34. - P. 1-3.

[29] Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009 // Hepatology. - 2009. - Vol. 50. - P. 1-36.

[30] Maeshiro T., Arakaki S., Watanabe T. et al. Different natural courses of chronic hepatitis B with genotypes B and C after the fourth decade of life // World J. Gastroenterol. - 2007, September 14. - Vol. 13. - P. 4560-4565.

[31] Manesis E.K. HBEAg-negative chronic hepatitis B: from obscurity to prominence // J. Hepatol. - 2006. - Vol. 45. - P. 343-346.

[32] Manno M., Gamma C., Schepis F. et al. Natural history of chronic HBV carriers in northern Italy morbidity and mortality after 30 years // Gastroenterology. - 2004. - Vol. 127. - P. 756-763.

[33] Marcellini P. Early HBSAg decline predicts sustained response to pegylated interferon // Hepatology. - 2009. - Vol. 49. - P. 1162.

[34] Marrero J.A., Lok A.S. Occult hepatitis B virus infection in patients with hepatocellular carcinoma: innocent bystander, cofactor, or culprit? // Gastroenterology. - 2004. - Vol. 126. - P. 347-350.

[35] Mast E.E., Alter M.J. Hepatitis C // Semin. Pediatr. Infect. Dis. - 1997. - Vol. 8. - P. 17-22.

[36] Morsica G., Ancarani F., Bagaglio S. et al. Occult hepatitis B virus infection in cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features // Infection. - 2009. - Vol. 37. - P. 445-449.

[37] Ni Y.H., Chang M.H., Huang L.M. et al. Hepatitis B virus infection in children and adolescente in a hyperendemic areci: 15 years after hepatitis B vaccination // Ann. Intern. Med. - 2001. - Vol. 135. - P. 796-800.

[38] Pang A., Yuen M.F., Yuan H.J. et al. Real-time quantification of hepatitis B virus core-promoter and pre-core mutants hepatitis E antigen seroconversion // J. Hepatol. - 2004. - Vol. 46. - P. 1008-1017.

[39] Prati D., Taioli E., Zanella A. et al. Updated definitions of healthy ranges for serum alanin aminotransferase levels // Ann. Intern. Med. - 2002. - Vol. 137. - P. 1-9.

[40] Raimondo G., Allain J.P., Brunetto M.R. Statements from the Taormina expert meeting on occult hepatitis B virus infection // J. Hepatol. - 2008. - Vol. 49. - P. 652-657.

[41] Salleras L., Dominguez A., Bruguera M. et al. Dramatic decline in acute hepatitis B infection and disease incidence rutes among. adolescents and young people after 12 years of a mass hepatitis B vaccination programme of preadolescents in the schools of Catalonia (Spain) // Vaccine. - 2005. - Vol. 23. - P. 2181-2184.

[42] Sancher-Tapias E.T., Costa J., Mas A. et al. Influence of hepatitis B virus genotype in long-term outcome of chronic hepatitis B in western patients // Gastroenterology. - 2002. - Vol. 18. - P. 1848-1856.

[43] Schaefers S. Hepatitis B virus: significance of genotypes // J. Viral. Hepat. - 2005. - Vol. 12. - P. 111-124.

[44] Squadrito G., Pollicino T., Cacciola J. et al. Occult hepatitis B virus infection in associated with the development of hepatocellular carcinoma in chronic hepatitis C patients // Cancer. - 2006. - Vol. 106. - P. 1326-1330.

[45] Thomopoulos K.C., Arvaniti V., Tsamantas A.C. et al. Pre-valence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and relationship with fibrosis // Eur. J. Gastroenterol. Hepatol. - 2006. - Vol. 18. - P. 233-237.

[46] Van Zonneveld M., van Nunen A.B., Niesters H.G. et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection // J. Viral. Hepatol. - 2003. - Vol. 10. - P. 294-297.

[47] Wiseman E., Holden S. Perinatal transmission of hepatitis B virus: an Australian experience // Med. J. Aust. - 2009. - Vol. 4, suppl. 190. - P. 489-492.

[48] Xu W.-M., Cui Y.-T., Wang L. et al. Lamivudin in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study // J. Viral. Hepatit. - 2009. - Vol. 16. - P. 94-103.

[49] Yeh S.H., Tsui C.Y., Kao J.H. et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve anulisis // J. Hepatol. - 2004. - Vol. 41. - P. 659-666.

[50] Yu A.S., Cheung R.C., Keeffe E.B. Hepatitis B vaccines // Clin. Liver Dis. - 2004. - Vol. 8. - P. 283-300.

[51] Zanetti A., Tanzi E., Romano L. et al. A prospective study on mother-to-infant transmission of hepatitis C virus // Intervirology. - 1998. - Vol. 41. - P. 208-212.

RIGHTS & PERMISSIONS

Enaleeva D.S.